Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
For EmblemHealth Medicare members with established cardiovascular disease who are overweight or obese, the cardiovascular risk reduction indication is coverable under Part D with prior authorization
It underscores how weight alone cannot be the full measure of success in obesity care, since heart outcomes ultimately matter most
Clinical trials demonstrated sustained weight loss of 10 to 22 percent over 68 weeks of treatment, substantially exceeding historical efficacy of lifestyle interventions and previous pharmacological agents
l_2), ii18ii26
We now have a weight control therapy that also significantly reduces cardiovascular events beyond the diabetes population where it was originally studied, said Wong
You can fill your prescription at your local pharmacy or contact the manufacturer, Novo Nordisk, for information on their distribution and patient support programs
